Open AccessCorrection of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion
Author(s) -
G. P. Arutyunov,
S. А. Boytsov,
М. И. Воевода,
О. М. Drapkina,
В. В. Кухарчук,
А. И. Мартынов,
Marina Shestakova,
V. S. Gurevich,
И. В. Сергиенко,
А. С. Алиева,
Н. М. Ахмеджанов,
М. Г. Бубнова,
А. S. Galyavich,
И. Г. Гордеев,
M. V. Yezhov,
Yu. A. Karpov,
В. О. Константинов,
С. В. Недогода,
Е. М. Нифонтов,
Yа A Orlova,
A. V. Panov,
С А Сайганов,
V. V. Skibitsky,
E. I. Tarlovskaya,
S. А. Urazgildeeva,
Yu. Sh. Khalimov
Publication year - 2019
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2019-9-44-51
Subject(s) - fenofibrate , medicine , hypertriglyceridemia , overweight , expert opinion , residual risk , gastroenterology , endocrinology , intensive care medicine , obesity , cholesterol , triglyceride
In opinion the Expert council provides management tactics for patients with hypertriglyceridemia (HTG). It is demonstrated that HTG is a common condition in overweight patients and is an important component of residual risk. HTG creates additional conditions for the progression of atherosclerosis, so the level of triglycerides (TG) is recommended to be measured in patients with a high, very high and extremely high risk level. An indication for the appointment of drugs that reduce the concentration of TG is its level of more than 2,3 mmol/L. Statins are the agents of choice to reduce the risk of cardiovascular disease in high-risk patients with hypercholesterolemia and HTG. Fenofibrate is used to correct HTG, and in case of intolerance to it or when the target level of TG is not reached, omega-3 ethers of polyunsaturated fatty acids in a dose of 2-4 g/day are recommended. In patients with HTG with a TG level >5,6 mmol/L, fenofibrate is the agent of choice.